Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5FABJ)

Drug Name
LAROPIPRANT Drug Info
Synonyms
Laropiprant; 571170-77-9; MK 0524; Cardaptive; MK-0524; UNII-G7N11T8O78; CHEMBL426559; G7N11T8O78; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid; Tedaptive; Laropiprant [USAN:INN:BAN]; [14C]-Laropiprant; Laropiprant/MK-0524; Laropiprant (INN/USAN); Laropiprant (MK-0524); SCHEMBL991107; AMOT0189; GTPL3356; KS-00000XIE; CTK8F0660; MK-0524B
Indication
Disease Entry ICD 11 Status REF
Coronary heart disease BA80.Z Phase 4 [1]
Arteriosclerosis BD40 Discontinued in Phase 3 [2]
Cross-matching ID
PubChem CID
9867642
ChEBI ID
CHEBI:135942
CAS Number
CAS 571170-77-9
TTD Drug ID
DM5FABJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Prostaglandin E2 receptor EP2 (PTGER2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [6]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [7]
Alprostadil DMWH7NQ Aorta coarctation Approved [8]
Iloprost DMVPZBE Pulmonary arterial hypertension BB01.0 Approved [9]
Omidenepag isopropyl DMUX7Z8 Glaucoma/ocular hypertension 9C61 Approved [10]
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [11]
CP-533536 DMZEJLB Osteoporosis FB83.0 Phase 2 [12]
Taprenepag DM1TSHL Glaucoma/ocular hypertension 9C61 Phase 2 [13]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
PF-4418948 DMMETU8 Endometriosis GA10 Phase 1 [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting HMG-CoA reductase (HMGCR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [15]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [16]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [17]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [18]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [19]
Fluvastatin DM4MDJY Arteriosclerosis BD40 Approved [16]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [20]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [16]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [21]
Teriflunomide DMQ2FKJ Hyperlipidaemia 5C80 Approved [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin D2 receptor 2 (PTGDR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Setipiprant DMZ61IA Asthma CA23 Phase 3 [22]
Fevipiprant DM4NX0C Asthma CA23 Phase 3 [23]
Ramatroban DMB8UQ3 Perennial allergic rhinitis CA08.03 Phase 2/3 [24]
AMG 853 DM973N4 Asthma CA23 Phase 2 [25]
ADC-3680 DM8GHIX Allergic rhinitis CA08.0 Phase 2 [26]
ARRY-502 DM17469 Allergic asthma CA23.0 Phase 2 [27]
QAV-680 DMIZYV1 Allergic rhinitis CA08.0 Phase 2 [28]
AP-761 DMISQOZ Asthma CA23 Phase 2 [29]
AZD1981 DMMCL9F Chronic obstructive pulmonary disease CA22 Phase 2 [30]
OC-000459 DM1JBD8 Allergy 4A80-4A85 Phase 2 [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin D2 receptor (PTGDR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Setipiprant DMZ61IA Asthma CA23 Phase 3 [32]
QAW-039 DMPCFXN Asthma CA23 Phase 3 [33]
AMG 853 DM973N4 Asthma CA23 Phase 2 [25]
ONO-4053 DMX4MVP Allergic rhinitis CA08.0 Phase 2 [34]
TS-022 DMMNXIW Atopic dermatitis EA80 Phase 2 [35]
S-555739 DMXDVNZ Allergy 4A80-4A85 Phase 2 [36]
MK-1029 DM8ZTW7 Asthma CA23 Phase 2 [26]
SAR-389644 DMA6O9R Allergic rhinitis CA08.0 Phase 1 [37]
192C86 DMQ8NTZ Thrombosis DB61-GB90 Phase 1 [38]
MK-1092 DMHS79I Type-1 diabetes 5A10 Phase 1 [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin F2-alpha receptor (PTGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [6]
Latanoprost DMI5OXG Ocular hypertension 9C61.01 Approved [40]
BOL-303259-X DM2EXC5 Open-angle glaucoma 9C61 Approved [41]
Tafluprost DMFC41K Glaucoma/ocular hypertension 9C61 Approved [42]
Carboprost Tromethamine DMS3508 Abortion JA00 Approved [43]
Travoprost DM20K91 Ocular hypertension 9C61.01 Approved [44]
PGF2ALPHA-IE DM5DAP3 Glaucoma/ocular hypertension 9C61 Phase 3 [45]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [46]
PDC-41 DM74YO8 Dysmenorrhea GA34.3 Phase 1 [47]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Thromboxane A2 receptor (TBXA2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alprostadil DMWH7NQ Aorta coarctation Approved [49]
Ridogrel DMWH9CN Acute myocardial infarction BA41 Approved [50]
Ramatroban DMB8UQ3 Perennial allergic rhinitis CA08.03 Phase 2/3 [51]
KP-496 DMCO8UZ Asthma CA23 Phase 2 [52]
FK-070 DMJSD5W Angina pectoris BA40 Phase 2 [53]
TAK-128 DMHPEFS Diabetic neuropathy 8C0Z Phase 2 [54]
Ifetroban sodium DMZP84Y Thrombosis DB61-GB90 Phase 2 [55]
Ifetroban DMEV39E Aspirin-induced asthma CA23.20 Phase 2 [56]
YM-57158 DMS31YW Allergic rhinitis CA08.0 Phase 1 [57]
G-619 DM3H6YC Thrombosis DB61-GB90 Phase 1 [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostacyclin receptor (PTGIR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Treprostinil DMTIQF3 Pulmonary arterial hypertension BB01.0 Approved [59]
Selexipag DMAHSU0 Pulmonary arterial hypertension BB01.0 Approved [60]
Epoprostenol DMUTYR2 Allergic rhinitis CA08.0 Approved [61]
Dinoprost Tromethamine DMXQKSL Abortion JA00 Approved [62]
Misoprostol DMHVJFK Medical abortion JA00.1Z Approved [62]
Beraprost DML634R Pulmonary hypertension BB01 Phase 4 [63]
esuberaprost DMXLGED Gout FA25 Phase 3 [64]
Ralinepag DM7G4Y9 Pulmonary arterial hypertension BB01.0 Phase 2 [65]
Clinprost DM6E5VA Asthma CA23 Discontinued in Preregistration [66]
Ataprost DMPTG39 Asthma CA23 Discontinued in Phase 3 [67]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [68]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [69]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [70]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [71]
Capsaicin DMGMF6V Back pain ME84.Z Approved [72]
Zafirlukast DMHNQOG Asthma CA23 Approved [73]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [70]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [74]
Fluconazole DMOWZ6B Cryptococcal meningitis Approved [71]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [70]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [75]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [68]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [76]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [71]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [70]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [70]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [77]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [78]
Capsaicin DMGMF6V Back pain ME84.Z Approved [79]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [80]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [3]
Prostacyclin receptor (PTGIR) TTOFYT1 PI2R_HUMAN Inhibitor [4]
Prostaglandin D2 receptor (PTGDR) TTNVEIR PD2R_HUMAN Inhibitor [4]
Prostaglandin D2 receptor 2 (PTGDR2) TTQDMX5 PD2R2_HUMAN Inhibitor [4]
Prostaglandin E2 receptor EP2 (PTGER2) TT1ZAVI PE2R2_HUMAN Inhibitor [4]
Prostaglandin F2-alpha receptor (PTGFR) TTT2ZAR PF2R_HUMAN Inhibitor [4]
Thromboxane A2 receptor (TBXA2R) TT2O84V TA2R_HUMAN Inhibitor [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Regulation of Drug Effects [5]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Regulation of Drug Effects [5]
UDP-glucuronosyltransferase 1A1 OTH1C8OJ UD11_HUMAN Biotransformations [5]
UDP-glucuronosyltransferase 1A3 OTUEOER3 UD13_HUMAN Biotransformations [5]
UDP-glucuronosyltransferase 1A9 OTPCHAFX UD19_HUMAN Biotransformations [5]
UDP-glucuronosyltransferase 2B7 OT2Q71VQ UD2B7_HUMAN Biotransformations [5]

References

1 ClinicalTrials.gov (NCT01126073) A Double Blind, Randomized Study to Compare Influence of Niacin/Laropiprant on Functional and Morphological Characteristics of Arterial Wall and Parameters of Inflammation in Subjects With Coronary Heart Disease Already Treated With a Statin in Miran Sebestjen, University Medical Centre Ljubljana.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023729)
3 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
4 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
5 Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans. Drug Metab Dispos. 2007 Feb;35(2):283-92. doi: 10.1124/dmd.106.011551. Epub 2006 Nov 28.
6 Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
8 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
9 Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
10 Clinical pipeline report, company report or official report of Santen Pharmaceutical.
11 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
12 Pfizer. Product Development Pipeline. March 31 2009.
13 A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
14 Clinical pipeline report, company report or official report of Tempest Therapeutics.
15 A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
16 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
17 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
18 Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
19 New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
20 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
21 Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
22 Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52.
23 Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207.
24 CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7.
25 Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
26 Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
27 Clinical pipeline report, company report or official report of Array BioPharma (Drug: ARRY-502).
28 Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91.
29 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028464)
30 Clinical pipeline report, company report or official report of AstraZeneca (2009).
31 Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy. 2013 Mar;68(3):375-85.
32 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
33 Effect Of QAW039, An Oral Prostaglandin D2 Receptor (DP2/CRTh2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Thoracic Society Journals. 2015.
34 Effect of ONO-4053, a DP1 (prostaglandin D2 receptor) Antagonist, on Prostaglandin D2-Induced Nasal Congestion. Journal of Allergy and Clinical Immunology Volume 135, Issue 2, Supplement, February 2015, Pages AB219.
35 Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis... Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14.
36 Clinical pipeline report, company report or official report of Shionogi (2011).
37 US patent application no. 2008,0300,217, Combination therapy with fumaric acid esters for the treatment of autoimmune and,or inflammatory disorders.
38 Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145.
39 The challenge of modulating -cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019 Jan;7(1):52-64.
40 PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
41 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
42 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
43 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
44 Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
45 Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
46 IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
47 THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97.
48 Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J. 2003 Apr 15;371(Pt 2):443-9.
49 Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.
50 Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42.
51 Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7.
52 Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
53 Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
54 ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
55 AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
56 Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19(2):97-115.
57 In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
58 G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
59 Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35.
60 Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80.
61 Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94.
62 Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58.
63 Prostaglandin I2 IP Receptor Agonist, Beraprost, Prevents Transient Global Cerebral Ischemia Induced Hippocampal CA1 Injury in Aging Mice. J Neurol Disord. 2014;2:1000174.
64 Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittelforschung. 1989 Apr;39(4):495-9.
65 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
66 Protective effect of a prostaglandin I2 analog, TEI-7165, on ischemic neuronal damage in gerbils. Brain Res. 1997 Sep 26;769(2):321-8.
67 Pharmacokinetics of intravenous ataprost alfadex, a new prostaglandin I2 analog in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1993 Aug;31(8):373-5.
68 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
69 Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
70 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
71 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
72 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
73 Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
74 The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
75 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
76 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
77 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
78 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
79 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
80 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.